Journal Mobile Options
Table of Contents
Vol. 28, No. 5, 2007
Issue release date: November 2007
Tumor Biol 2007;28:253–263
(DOI:10.1159/000110898)

Quantification of CD44v6 and EGFR Expression in Head and Neck Squamous Cell Carcinomas Using a Single-Dose Radioimmunoassay

Nestor M. · Ekberg T. · Dring J. · van Dongen G.A.M.S. · Wester K. · Tolmachev V. · Anniko M.
aUnit of Otolaryngology and Head and Neck Surgery, Department of Surgical Sciences, and bUnit of Biomedical Radiation Science, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden; cDepartment of Otolaryngology/Head and Neck Surgery, Free University Medical Center, Amsterdam, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: In the growing field of tumor targeting, there is an urgent need to profile suitable molecular targets. In this study, CD44v6 and EGFR expression was quantified in samples of patients with head and neck squamous cell carcinoma (HNSCC) using a single-dose (SD) radioimmunoassay. Methods: The SD radioimmunoassay using 125I-chimeric monoclonal antibody (cMAb) U36 and 125I-cMAb cetuximab was first validated and then applied to quantify the expression of their target antigen molecules, CD44v6 and EGFR, in patient samples. Results were compared to immunohistochemical staining. Results: The SD assay provided sensitive quantitative values of the molecular targets studied, generally agreeing with the immunohistochemistry (IHC) results. The results indicated that expression of CD44v6 (0.2–20 nmol/µg membrane) was generally higher than that of EGFR (0.6–2.3 nmol/µg membrane) in the tumor samples analyzed, which corresponded to an average of 700,000 and 90,000 antigen molecules per cell, respectively. Conclusions: The SD radioimmunoassay is simple, reliable, and can be performed on a small amount (50 mg) of tissue. This assay could be a useful tool in the growing field of personalized cancer therapy, and can be used as a complement to IHC. In the tumors studied, CD44v6 was generally expressed at a higher level than EGFR, which might suggest that it could be more readily targeted by MAbs.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer, 2001;1:118–129.
  2. Reff ME, Hariharan K, Braslawsky G: Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002;9:152–166.

    External Resources

  3. Stern M, Herrmann R: Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005;54:11–29.
  4. Baselga J: Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001;19(suppl 18):41S–44S.
  5. Baselga J: Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 2002;20:2217–2219.
  6. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593–1611.
  7. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550–6565.
  8. Funaro A, Horenstein AL, Santoro P, Cinti C, Gregorini A, Malavasi F: Monoclonal antibodies and therapy of human cancers. Biotechnol Adv 2000;18:385–401.
  9. Srivastava S: Molecular screening of cancer: the future is here. Mol Diagn Ther 2006;10:221–230.
  10. Montero C: The antigen-antibody reaction in immunohistochemistry. J Histochem Cytochem 2003;51:1–4.
  11. Moorghen M, Ince P, Finney KJ, Watson AJ, Harris AL: Epidermal growth factor receptors in colorectal carcinoma. Anticancer Res 1990;10:605–611.
  12. Ohman L, Gedda L, Hesselager G, Larsson R, Nister M, Stigbrand T, Wester K, Carlsson J: A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumor Biol 2002;23:61–69.
  13. Hilbe W, Dlaska M, Dirnhofer S, Duba HC, Eisterer W, Oberwasserlechner F, Mildner A, Schmid T, Ammann K, Thaler J, Woll E: Characterisation and predictive value of epidermal growth factor receptor status using quantitative real-time PCR combined with immunohistochemistry on non-small cell lung cancer specimens. Int J Oncol 2003;23:893–899.
  14. Junttila TT, Laato M, Vahlberg T, Soderstrom KO, Visakorpi T, Isola J, Elenius K: Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 2003;9:5346–5357.
  15. Nagatsuka H, Ishiwari Y, Tsujigiwa H, Nakano K, Nagai N: Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol 2001;37:599–604.
  16. Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E: Quantitative PCR – new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest 2004;64:511–522.
  17. Lopez-Guerrero JA, Bolufer-Gilabert P, Vera-Sempere FJ, Marugan de la Concha I, Barragan-Gonzalez E: C-erbB-2 expression and its relationship with ploidy, p53 abnormalities and epidermal growth factor receptor content in human non-small cell lung cancer. Clin Chim Acta 1999;285:105–120.
  18. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK: Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci USA 2003;100:9330–9335.
  19. Kopp R, Ruge M, Rothbauer E, Cramer C, Kraemling HJ, Wiebeck B, Schildberg FW, Pfeiffer A: Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 2002;22:1161–1167.
  20. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988;48:137–141.
  21. Brakenhoff RH, van Gog FB, Looney JE, van Walsum M, Snow GB, van Dongen GA: Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol Immunother 1995;40:191–200.
  22. Schrijvers AH, Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, van Dongen GA: MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993;53:4383–4390.
  23. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311–1318.
  24. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787–2799.
  25. van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, van Dongen GA: High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 1997;80(suppl 12):2360–2370.
  26. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
  27. Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, Frenay M, Francois E, Milano G: Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Res Treat 1991;17:211–219.
  28. Jaramillo ML, Leon Z, Grothe S, Paul-Roc B, Abulrob A, O’Conner McCourt M: Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 2006;312:2778–2790.
  29. Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA: Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000;41:1999–2010.
  30. Nestor M, Persson M, van Dongen GA, Jensen HJ, Lundqvist H, Anniko M, Tolmachev V: In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2005;32:1296–1304.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50